Investigating Big Pharma Licensing Trends
AstraZeneca’s Licensing Tactics Make It Top Dealmaker
Executive Summary
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.